Data as of Jul 23
| +0.16 / +1.18%|
The 7 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 21.00, with a high estimate of 25.00 and a low estimate of 16.00. The median estimate represents a +53.17% increase from the last price of 13.71.
The current consensus among 8 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.